Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology

Inclusion Criteria:

* To be included in this study the patient must:

  1. Be 18 years or older.
  2. Have a confirmed or likely diagnosis of HGSOC, breast cancer, prostate cancer, pancreatic mass, liver mass, renal mass or brain tumour.
  3. Be aware of their diagnosis.
  4. Be a likely surgical candidate who is fit for possible surgery.
  5. Have no contraindications to the use of the IV contrast agents involved in this study.
  6. Be able to provide written informed consent according to ICH/GCP, national and local regulations.
  7. Volunteers of childbearing potential must have a negative pregnancy test, either urinary or blood prior to enrolment.
  8. Have ECOG performance status 0 or 1.
  9. Express willingness and ability to comply with scheduled visits, laboratory tests, imaging and other study procedures.

Exclusion Criteria:

* The presence of any of the following will preclude the patient from the study:

  1. Any disorder that may adversely affect levels of pyruvate or lactate such as diabetes mellitus.
  2. The use of medications that may affect levels of pyruvate or lactate such as metformin or insulin.
  3. Known allergy or adverse reaction to any of the injected contrast agents proposed for use in this study.
  4. Pregnancy or breastfeeding.
  5. Other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or in the judgement of the investigators make it undesirable for the patient to enter the study.
  6. Laboratory abnormalities that may have an unknown or unpredictable impact on study results.
  7. Not suitable for MR scanning e.g. severe obesity, inability to lie still or contraindicated metal implants such as the intrauterine contraceptive device.